- Email: [email protected]
5288853 Factor VIII purification process
PATENT ABSTRACTS
608
ture modifying agent(s). In this instance, the mutation is promoted by the host cell, and the mutant material may thereafter be isolated and recovered. Diagnostic methods employing the principles of the invention are also disclosed.
5288622
responses against human respiratory syncytial virus. The DNA compositions include structural genes coding for the glycoproteins and expression and replication plasmids containing the structural genes. Host cells transformed with the above DNA compositions, vaccines made from the glycoproteins and methods for protecting humans by inoculation with said vaccines are also part of this invention.
HUMAN NERVE GROWTH F A C T O R BY RECOMBINANT TECHNOLOGY Alane Gray, Axe Ullrich assigned to Genentech Inc The beta-subunit of human nerve growth factor (betaNGF) is prepared in essentially pure form in commercially viable quantities using recombinant DNA technology. The nucleotide sequence and vectors encoding human betaNGF and host cells transformed with the vectors are also provided.
5288852 HUMAN TUMOR NECROSIS FACTOR POLYPEPTIDES Masaak Yamada, Yasuji Furutani, Mitsue Notake, Juniti Yamagishi, Kyoto, Japan assigned to Dainippon Pharmaceutical Co Ltd A novel cloned DNA encoding a human tumor necrosis factor (TNF), a vector having said DNA inserted thereinto, a host transformed with said vector and a novel human TNF polypeptide, and processes for producing them.
5288624 CERCOSPORAL FUNGICIDE COMPOSITIONS AND METHODS OF USE
5288853 Ruby I Nielsen, Farum, Denmark assigned to Novo Nordisk A/S The present invention relates to a funcidally active principle (fungicidal agent) obtainable by cultivation of fungi of the genus Phaeoramularia or Cercospora. The principle can be used for controlling fungi in plants and animals, including mammals.
5288630 EXPRESSION SYSTEM FOR RSV GLYCOPROTEIN F AND G Michael W Wathen assigned to The Upjohn Company This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune
FACTOR VIII PURIFICATION PROCESS Prabir Bhattacharva, Toshiharu Motokubota assigned to Alpha Therapeutic Corporation There is provided in accordance with the practice of this invention a process for separating Factor VII1 complex from an impure protein fraction containing Factor VIII complex. An aqueous solution of the impure protein fraction containing Factor VIII complex is applied to a heparin-coupled chromatographic medium, to bind the Factor VIII complex to the medium. The Factor VIII is then recovered from the heparin-coupled chromatographic medium by elution with an aqueous solution comprising CaC12 and histidine. The recovered Factor VIII is further purified by precipitation with a solution comprising glyeine and NaCI, and washing the resultant precipitate with a solution comprising histidine, glycine, and NaCI to provide a Factor VIII complex solution with a specific activity of about 70 to about 150 units/mg.
608
ture modifying agent(s). In this instance, the mutation is promoted by the host cell, and the mutant material may thereafter be isolated and recovered. Diagnostic methods employing the principles of the invention are also disclosed.
5288622
responses against human respiratory syncytial virus. The DNA compositions include structural genes coding for the glycoproteins and expression and replication plasmids containing the structural genes. Host cells transformed with the above DNA compositions, vaccines made from the glycoproteins and methods for protecting humans by inoculation with said vaccines are also part of this invention.
HUMAN NERVE GROWTH F A C T O R BY RECOMBINANT TECHNOLOGY Alane Gray, Axe Ullrich assigned to Genentech Inc The beta-subunit of human nerve growth factor (betaNGF) is prepared in essentially pure form in commercially viable quantities using recombinant DNA technology. The nucleotide sequence and vectors encoding human betaNGF and host cells transformed with the vectors are also provided.
5288852 HUMAN TUMOR NECROSIS FACTOR POLYPEPTIDES Masaak Yamada, Yasuji Furutani, Mitsue Notake, Juniti Yamagishi, Kyoto, Japan assigned to Dainippon Pharmaceutical Co Ltd A novel cloned DNA encoding a human tumor necrosis factor (TNF), a vector having said DNA inserted thereinto, a host transformed with said vector and a novel human TNF polypeptide, and processes for producing them.
5288624 CERCOSPORAL FUNGICIDE COMPOSITIONS AND METHODS OF USE
5288853 Ruby I Nielsen, Farum, Denmark assigned to Novo Nordisk A/S The present invention relates to a funcidally active principle (fungicidal agent) obtainable by cultivation of fungi of the genus Phaeoramularia or Cercospora. The principle can be used for controlling fungi in plants and animals, including mammals.
5288630 EXPRESSION SYSTEM FOR RSV GLYCOPROTEIN F AND G Michael W Wathen assigned to The Upjohn Company This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune
FACTOR VIII PURIFICATION PROCESS Prabir Bhattacharva, Toshiharu Motokubota assigned to Alpha Therapeutic Corporation There is provided in accordance with the practice of this invention a process for separating Factor VII1 complex from an impure protein fraction containing Factor VIII complex. An aqueous solution of the impure protein fraction containing Factor VIII complex is applied to a heparin-coupled chromatographic medium, to bind the Factor VIII complex to the medium. The Factor VIII is then recovered from the heparin-coupled chromatographic medium by elution with an aqueous solution comprising CaC12 and histidine. The recovered Factor VIII is further purified by precipitation with a solution comprising glyeine and NaCI, and washing the resultant precipitate with a solution comprising histidine, glycine, and NaCI to provide a Factor VIII complex solution with a specific activity of about 70 to about 150 units/mg.